Related Experiment Video
Updated: Jun 29, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.4K
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer Journal (Sudbury, Mass.)
|March 25, 2024
Summary
Intratumoral therapies offer a promising approach for melanoma treatment by stimulating immune responses. This review covers approved therapies like talimogene laherparepvec and emerging treatments including oncolytic viruses and mRNA injections.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Intratumoral therapies are well-suited for melanoma due to accessible lesions.
- Many intratumoral therapies aim to stimulate anti-tumor immune responses, aligning with melanoma's immunogenic nature.
Approach:
- This review examines the US Food and Drug Administration-approved intratumoral therapy, talimogene laherparepvec.
- It also explores emerging intratumoral therapy classes, including novel oncolytic viruses, mRNA-based injections, and cytokines.
Key Points:
- Talimogene laherparepvec is an approved intratumoral therapy for melanoma.
- Developing intratumoral therapies include oncolytic viruses, mRNA injections, and cytokines.
- These therapies leverage the accessibility of melanoma lesions and the potential to stimulate anti-tumor immunity.
Conclusions:
- Intratumoral therapies provide a unique and effective strategy for melanoma treatment.
- The field is rapidly advancing with new oncolytic viruses, mRNA technology, and immunomodulatory agents.
- Further research into these diverse intratumoral approaches holds significant promise for improving melanoma patient outcomes.
